Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Healthcare investors are observing signs of recovery across several segments of the industry. Danaher (NYSE:DHR) is experiencing growth due to increased demand in life sciences, while Medtronic (NYSE:MDT) is showing progress from years of investment in new products and operational execution. The investors are trying to determine which recovery story presents greater long-term upside potential.

Medtronic's turnaround is being driven by its growth platforms, which are now contributing significantly to revenue. Its latest fiscal quarter results indicate a 9.9% revenue growth, with organic growth at 6.6%. Danaher's recovery hinges on improving spending across its life sciences business, which has shown the strongest performance in years.

However, Medtronic's recovery has largely come from a few fast-growing platforms, and investors will need to see broader growth across the company before considering its turnaround complete.